Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Adenosine Cardioplegia; Improved Cardioprotection?

This study has been completed.
Information provided by (Responsible Party):
University Hospital of North Norway Identifier:
First received: April 30, 2010
Last updated: September 29, 2011
Last verified: September 2011
60 elective patients for CABG will be included to receive either standard hyperkalemic cardioplegia (St.Thomas Hospital Solution No I) or cardioplegia where supranormal potassium is replaced with 1.2 mM adenosine. Hypothesis as follows: 1. Adenosine instead of supranormal potassium in the cardioplegic solution give satisfactory cardiac arrest. 2. Adenosine instead of supranormal potassium in the cardioplegic solution gives equal cardioprotection. The patients will be followed with PiCCO-catheter to monitor cardiac function and repetitive blood samples to measure release of cardiac enzymes.

Condition Intervention Phase
Angina Pectoris
Drug: Adenosine
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Adenosine Instead of Supranormal Potassium in Crystalloid Cardioplegia, a Randomized Clinical Study

Resource links provided by NLM:

Further study details as provided by University Hospital of North Norway:

Primary Outcome Measures:
  • Release of cardiac enzymes (TnT and CKMB) [ Time Frame: First 48 hour postoperatively ]
    Repeatedly measured postoperatively.

Secondary Outcome Measures:
  • PiCCO [ Time Frame: First 24 hours postoperatively ]
    Measurement of cardiac function and hemodynamics the first 24 hours postoperatively

  • Endothelial injury [ Time Frame: Peroperatively (before crossclamping aorta and after 5 minutes of reperfusion) ]
    Measurements of markers of endothelial injury/dysfunction peroperatively. Blood will be sampled immediately before cross-clamping the aorta and after 5 minutes of reperfusion.

Estimated Enrollment: 60
Study Start Date: April 2010
Study Completion Date: September 2011
Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Adenosine cardioplegia
Adenosine cardioplegia
Drug: Adenosine
1.2 mM adenosine instead of supranormal potassium in the cardioplegic solution
Active Comparator: Control
Standard hyperkalemic cardioplegia
Drug: Adenosine
1.2 mM adenosine instead of supranormal potassium in the cardioplegic solution


Ages Eligible for Study:   40 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Elective patients
  • Ejection fraction > 40%
  • Age 40-75
  • No release og TnT or CKMB within last week before CABG
  • Pure CABG

Exclusion Criteria:

  • Age >75 or < 40
  • EF < 40%
  • Emergency operations
  • Unstable angina
  • Release of TnT or CKMB within the week before operation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01123525

University Hospital of North Norway
Troomsø, Norway, 9038
Sponsors and Collaborators
University Hospital of North Norway
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: University Hospital of North Norway Identifier: NCT01123525     History of Changes
Other Study ID Numbers: AdCard 2010
2008-004274-40 ( EudraCT Number )
Study First Received: April 30, 2010
Last Updated: September 29, 2011

Additional relevant MeSH terms:
Angina Pectoris
Chest Pain
Neurologic Manifestations
Nervous System Diseases
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Signs and Symptoms
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Vasodilator Agents
Purinergic P1 Receptor Agonists
Purinergic Agonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on April 26, 2017